Uyku

Doxepin is a tricyclic compound with a remarkably dose-dependent pharmacological profile. At higher doses (75-300 mg), it functions as a traditional tricyclic antidepressant (TCA) with activity across multiple neurotransmitter systems. However, at ultra-low doses (3-6 mg), doxepin acts almost exclusively as a highly selective histamine H1 receptor antagonist, making it one of the most targeted sleep maintenance agents available. This ultra-low dose formulation was approved by the FDA in 2010 under the brand name Silenor specifically for the treatment of insomnia characterized by difficulty with sleep maintenance. The distinction between high-dose and ultra-low dose doxepin is critical: at 3-6 mg, the drug avoids the anticholinergic, noradrenergic, and serotonergic side effects that characterize tricyclic antidepressants, resulting in a remarkably clean side effect profile. For biohackers and those seeking a non-habit-forming sleep aid, ultra-low dose doxepin offers a compelling option -- it does not produce dependence, does not cause rebound insomnia upon discontinuation, and maintains efficacy with long-term use. Unlike benzodiazepines and Z-drugs, it carries no abuse potential and is not a scheduled substance.

DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.

Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.

Oral compound activating ghrelin receptors to trigger growth hormone release while preserving natural production. Achieves superior oral bioavailability exceeding 60% with a 24-hour half-life, making it unique among GH secretagogues for its convenient once-daily oral dosing.

Phenibut (beta-phenyl-gamma-aminobutyric acid) is a synthetic GABA analog developed in the Soviet Union in the 1960s. It was designed to cross the blood-brain barrier, which GABA itself cannot do efficiently, by adding a phenyl ring to the GABA molecule. Phenibut has been prescribed in Russia and several former Soviet states since the 1960s for the treatment of anxiety, insomnia, post-traumatic stress disorder, vestibular disorders, and stuttering. It was famously included in the medical kit of Soviet cosmonauts for its calming effects without impairing cognitive performance. Phenibut is NOT approved by the FDA, EMA, or any Western regulatory agency as a pharmaceutical drug. In the United States, Australia, and parts of Europe, it has been sold as a dietary supplement or nootropic, though several countries have moved to restrict or ban its sale due to growing reports of dependence, withdrawal, and adverse events. The addiction and dependence potential of phenibut is HIGH, and tolerance develops rapidly with repeated use. This compound should be treated with the same caution as benzodiazepines or other GABAergic drugs.

Developed in Russia, Pinealon demonstrates unique DNA-interaction for neuroprotection and cognitive enhancement. Benefits traumatic brain injury recovery and age-related cognitive decline with excellent safety profile.

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes.